Humedix Co., Ltd. Logo

Humedix Co., Ltd.

200670.KQ

(0.0)
Stock Price

36.150,00 KRW

4.26% ROA

14.72% ROE

34.08x PER

Market Cap.

353.445.041.700,00 KRW

23.48% DER

0% Yield

17.39% NPM

Humedix Co., Ltd. Stock Analysis

Humedix Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Humedix Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Humedix Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Humedix Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Humedix Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Humedix Co., Ltd. Revenue
Year Revenue Growth
2015 42.133.250
2016 47.133.616 10.61%
2017 54.727.015 13.88%
2018 64.831.668 15.59%
2019 78.618.778 17.54%
2020 98.480.868 20.17%
2021 121.472.504 18.93%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Humedix Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 3.323.376
2016 4.685.058 29.06%
2017 4.246.752 -10.32%
2018 5.183.823 18.08%
2019 5.621.572 7.79%
2020 7.678.033 26.78%
2021 35.727.008 78.51%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Humedix Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 2.476.369
2016 2.803.515 11.67%
2017 4.509.644 37.83%
2018 5.531.554 18.47%
2019 7.699.881 28.16%
2020 8.785.003 12.35%
2021 -18.129.160 148.46%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Humedix Co., Ltd. EBITDA
Year EBITDA Growth
2015 15.551.962
2016 15.074.630 -3.17%
2017 16.567.677 9.01%
2018 17.798.777 6.92%
2019 22.156.720 19.67%
2020 27.160.206 18.42%
2021 31.388.240 13.47%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Humedix Co., Ltd. Gross Profit
Year Gross Profit Growth
2015 21.668.993
2016 22.480.298 3.61%
2017 24.591.258 8.58%
2018 25.620.706 4.02%
2019 32.798.800 21.89%
2020 39.396.326 16.75%
2021 51.481.660 23.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Humedix Co., Ltd. Net Profit
Year Net Profit Growth
2015 11.622.597
2016 10.274.737 -13.12%
2017 11.940.469 13.95%
2018 9.207.792 -29.68%
2019 10.420.174 11.63%
2020 15.084.078 30.92%
2021 3.297.588 -357.43%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Humedix Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 1.245
2016 1.091 -14.22%
2017 1.316 17.17%
2018 963 -36.66%
2019 1.094 11.89%
2020 1.587 31.13%
2021 351 -352.14%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Humedix Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2015 1.034.356
2016 -14.752.603 107.01%
2017 -10.633.888 -38.73%
2018 10.821.342 198.27%
2019 4.477.386 -141.69%
2020 6.070.286 26.24%
2021 1.736.911 -249.49%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Humedix Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 11.706.215
2016 7.609.285 -53.84%
2017 8.765.496 13.19%
2018 23.802.879 63.17%
2019 13.809.722 -72.36%
2020 23.762.116 41.88%
2021 5.479.662 -333.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Humedix Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 10.671.859
2016 22.361.888 52.28%
2017 19.399.384 -15.27%
2018 12.981.537 -49.44%
2019 9.332.336 -39.1%
2020 17.691.830 47.25%
2021 3.742.751 -372.7%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Humedix Co., Ltd. Equity
Year Equity Growth
2015 109.802.416
2016 113.008.083 2.84%
2017 113.908.655 0.79%
2018 113.678.299 -0.2%
2019 121.371.830 6.34%
2020 134.877.159 10.01%
2021 141.952.220 4.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Humedix Co., Ltd. Assets
Year Assets Growth
2015 115.899.949
2016 131.158.761 11.63%
2017 129.739.260 -1.09%
2018 128.275.533 -1.14%
2019 138.421.304 7.33%
2020 175.646.541 21.19%
2021 215.861.747 18.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Humedix Co., Ltd. Liabilities
Year Liabilities Growth
2015 5.755.032
2016 18.150.678 68.29%
2017 15.830.604 -14.66%
2018 14.597.233 -8.45%
2019 17.049.474 14.38%
2020 40.769.381 58.18%
2021 73.909.526 44.84%

Humedix Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
11803.93
Net Income per Share
964.01
Price to Earning Ratio
34.08x
Price To Sales Ratio
3184.41x
POCF Ratio
16.1
PFCF Ratio
64956.39
Price to Book Ratio
2.45
EV to Sales
3184.32
EV Over EBITDA
12504.88
EV to Operating CashFlow
18422.95
EV to FreeCashFlow
64954.67
Earnings Yield
0.03
FreeCashFlow Yield
0
Market Cap
353,45 Bil.
Enterprise Value
353,44 Bil.
Graham Number
17047.77
Graham NetNet
565.18

Income Statement Metrics

Net Income per Share
964.01
Income Quality
2.12
ROE
0.07
Return On Assets
0.12
Return On Capital Employed
0.17
Net Income per EBT
0.77
EBT Per Ebit
0.93
Ebit per Revenue
0.24
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.09
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.6
Operating Profit Margin
0.24
Pretax Profit Margin
0.23
Net Profit Margin
0.17

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.42
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2040.26
Free CashFlow per Share
578.67
Capex to Operating CashFlow
-0.72
Capex to Revenue
-0.12
Capex to Depreciation
-1.12
Return on Invested Capital
0.09
Return on Tangible Assets
0.04
Days Sales Outstanding
72.91
Days Payables Outstanding
17.23
Days of Inventory on Hand
89.91
Receivables Turnover
5.01
Payables Turnover
21.19
Inventory Turnover
4.06
Capex per Share
-1461.58

Balance Sheet

Cash per Share
5.780,44
Book Value per Share
13.398,90
Tangible Book Value per Share
14757.78
Shareholders Equity per Share
13398.9
Interest Debt per Share
3145.53
Debt to Equity
0.23
Debt to Assets
0.14
Net Debt to EBITDA
-0.33
Current Ratio
3.06
Tangible Asset Value
0,14 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
0.23
Working Capital
0,08 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
17766240
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Humedix Co., Ltd. Dividends
Year Dividends Growth
2015 300
2016 500 40%
2022 500 0%

Humedix Co., Ltd. Profile

About Humedix Co., Ltd.

Humedix Co., Ltd., a healthcare company, researches, develops, manufactures, and sells various pharmaceutical products in South Korea. It offers over-the-counter drugs, prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic products, and functional synthetic materials, as well as health functional foods. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. The company was founded in 2002 and is headquartered in Anyang-si, South Korea.

CEO
Jin-hwan Kim
Employee
226
Address
603, 268, Hagui-ro
Anyang-Si, 14056

Humedix Co., Ltd. Executives & BODs

Humedix Co., Ltd. Executives & BODs
# Name Age
1 Jin-hwan Kim
Chief Executive Officer
70

Humedix Co., Ltd. Competitors

Vieworks Co., Ltd. Logo
Vieworks Co., Ltd.

100120.KQ

(0.0)
InBody Co.,Ltd Logo
InBody Co.,Ltd

041830.KQ

(0.0)
Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
GeneOne Life Science, Inc. Logo
GeneOne Life Science, Inc.

011000.KS

(1.0)